NCI-2022-10927

A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors

This is a Phase 1 study happening at multiple centers to test AZD9592 in people with advanced solid tumors (cancers that are hard to treat or have spread). This is a first-in-human study, meaning it’s the first time the drug is being tested in people. The study will test AZD9592 on its own and in combination with other cancer treatments. It will look at how safe the drug is, how it works in the body, and how well it can treat these cancers. The study will start by testing low doses of the drug and then increase the dose to find the best amount to use.

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05647122

Clinical Trial Site: Sinai

To see all available clinical trials click here.